Otros proyectos internacionales

El IDIBAPS/FCRB también recibe financiación de otras entidades extranjeras que ofrecen convocatorias de financiación competitivas. Estas entidades suelen ser organizaciones benéficas, fundaciones o empresas privadas.

ANALYSIS OF THE CHROMATIN ACCESIBILITY LANDSCAPE AND REGULATORY NETWORKS OF IgM MONOCLONAL GAMMOPATHIES: TOWARDS A BETTER UNDERSTANDING OF PROGRESSION MECHANISMS

IP: FERNANDEZ DE LARREA RODRIGUEZ, CARLOS JO
Financiador: International Waldenstrom's Macroglobulinemia Foundation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: IWMF_SMI_22_01
Importe: 76.805,16 €
Duración: 26/10/2022 to 25/04/2024

TIC Genetics - 1/7-Collaborative Genomics Studies of Tourette Disorder

IP: MORER LIÑAN, ASTRID
Financiador: ACADEMISCH ZIEKENHUIS GRONINGEN
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 671128
Importe: 49.956,31 €
Duración: 15/06/2018 to 30/04/2024

Intra-tumoral heterogeneity and clinical impact in HER2-positive and triple-negative early breast cancer

IP: PRAT APARICIO, ALEIX
Financiador: Breast Cancer Research Foundation - BCRF
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 988310
Importe: 224.596 €
Duración: 01/10/2022 to 30/09/2024

Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

IP: PRAT APARICIO, ALEIX
Financiador: Breast Cancer Research Foundation - BCRF
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: BCRF_AAP_01
Importe: 209.086,18 €
Duración: 01/10/2023 to 30/09/2024

In-vitro activity of CD5CAR-NK cells against moulds causing invasive fungal disease

IP: PUERTA ALCALDE, PEDRO
Financiador: European Society of Clinical Microbiolog and Infectious Diseases (ESCMID)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ESCMID_22_1
Importe: 19.998 €
Duración: 01/04/2023 to 30/09/2024

Efecto del Tratamiento agudo con corticoides endovenosos en las partes blandas en fracturas de pilón tibial, retropié y mediopié en relación con tiempo desde ingreso hasta tratamiento quirúrgico

IP: GARCIA ELVIRA, RUBEN
Financiador: AO Foundation AO Global Networks
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 2021-AOTESASPAIN_003
Importe: 7.254,75 €
Duración: 15/01/2022 to 30/10/2024

Multicentre assessment of nasal swabbing approach: alpha-syn RT QuIC assay diagnostic performance inolfactory mucosa and cerebrospinal fluid in patients with prodromal PD, PD or PD with neurocognitive impairment

IP: MARTI DOMENECH, MARIA JOSEFA
Financiador: UNIVERSITA DEGLI STUDI DI VERONA
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-021307
Importe: 100.322,37 €
Duración: 01/04/2022 to 30/11/2024

Identifying New Therapeutic Targets in Obesity-Driven Liver Cancer

IP: FERNANDEZ LOBATO, MERCEDES
Financiador: INSTITUT RECERCA BIOMEDICA BARCELONA (IRB)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 1766
Importe: 136.893 €
Duración: 01/01/2021 to 31/12/2024

Deciphering the mechanism underlying ECP-induced immunomodulation in kidney transplantation

IP: ROVIRA JUAREZ, JORDI
Financiador: European Society for Organ Transplantation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ESOT_ECP_23_01
Importe: 50.000 €
Duración: 01/01/2024 to 31/12/2024

Fetal doppler for antenatal risk stratification.

IP: BIJNENS, BART
Financiador: AGA KHAN UNIVERSITY
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: INV-021528
Importe: 566.436 €
Duración: 01/01/2021 to 31/12/2024

Phospho-proteome analysis of PBMCs in LRRK2 mutations carriers: expansion & validation of findings of the Barcelona LRRK2 Biorepository

IP: FERNANDEZ SANTIAGO, RUBEN
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-000858
Importe: 77.928,07 €
Duración: 01/08/2021 to 31/12/2024

PPMI - Parkinson's Progression Markers Initiative (PPMI) study

IP: ALDECOA ANSORREGUI, IBAN
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-024484
Importe: 52.683,78 €
Duración: 01/01/2021 to 31/12/2024

What works and why? Eye movement desensitization and reprocessing a potential treatment for substance use disorders

IP: MIQUEL DE MONTAGUT, LAIA
Financiador: EMDR Foundation Eye Movement Desensitization & reprocess
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 2022-02
Importe: 9.000 €
Duración: 01/04/2023 to 31/03/2025

Effectivenessof an EMDR intervention for the prevention of post-traumatic symptoms in perinatal loss

IP: TORRES GIMENEZ, ANNA
Financiador: EMDR Foundation Eye Movement Desensitization & reprocess
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 2022-03
Importe: 7.500 €
Duración: 01/04/2023 to 31/03/2025

HeBA - Barcelona 2022 PPMI Healthy Brain Aging Initiative

IP: MARTI DOMENECH, MARIA JOSEFA
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-022187
Importe: 968.050,79 €
Duración: 31/05/2022 to 30/05/2025

Dual CD19-CART approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

IP: PEREZ GALAN, PATRICIA
Financiador: International Follicular Lymphoma Challenge
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MILKEN_FLF_22_01
Importe: 385.335,7 €
Duración: 01/12/2022 to 30/06/2025

Effects of circulating extracellular vesicles on pancreatic islets during obesity

IP: SERVITJA DUQUE, JOAN MARC
Financiador: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EFSD/BOEHR_22_01
Importe: 100.000 €
Duración: 09/01/2023 to 08/07/2025

MOLECULAR MEASURABLE RESIDUAL DISEASE (MRD) MONITORING BY HIGH-THROUGHPUT TECHNIQUES IN PATIENTS TREATED WITH CART19 THERAPY

IP: LOPEZ GUERRA, MONICA
Financiador: Thermo fisher scientific inc.
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: THERMOONCOCRG_22_01
Importe: 186.393,29 €
Duración: 28/06/2023 to 31/08/2025

RIBOLARIS-PREDICT - Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

IP: PRAT APARICIO, ALEIX
Financiador: Breast Cancer Research Foundation - BCRF
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: BCRF_AAP_24
Importe: 200.213,66 €
Duración: 01/10/2024 to 30/09/2025

Novel biomarkers related to sleep-wake alterations in Alzheimer's disease

IP: FALGAS MARTINEZ, NEUS
Financiador: Alzheimer's Association
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: AACSF-21-723056
Importe: 151.178,86 €
Duración: 01/11/2021 to 31/10/2025

Molecular dissection of exosome-mediated bis(monocylglycero)phosphate release in Parkinson's disease-related LRRK2 dysfunction.

IP: FERNANDEZ SANTIAGO, RUBEN
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-023914
Importe: 10.582 €
Duración: 01/11/2023 to 31/10/2025

Early detection of perianal fistulizing disease- Pathophysiology and Imaging

IP: SALAS MARTINEZ, MARIA AZUCENA
Financiador: THE LEONA M & HARRY B HELMSLEY CHARITABLE TRUST
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 2008-04050
Importe: 1.745.753 €
Duración: 25/11/2019 to 24/11/2025

HUNTER: Hepatocellular Carcinoma Expediter Network

IP: LLOVET BAYER, JOSEP MARIA
Financiador: Newcastle University Accounts Payable
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: AA_17_03
Duración: 01/11/2018 to 30/11/2025

Psoriasis, a metabolic dysregulation of the innate immune system? Targeting ZEB1 in macrophages as a new therapeutic approach to psoriasis

IP: POSTIGO ANGON, ANTONIO ANDRES
Financiador: LEO FOUNDATION
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LEO_19_01
Importe: 491.478 €
Duración: 01/03/2020 to 31/12/2025

Estudio comparativo biomecánico de dos métodos de osteosíntesis para fracturas de meseta tibial Schatzker tipo I

IP: RENAU CERRILLO, MARINA
Financiador: AO Foundation AO Global Networks
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: AOTRAUMA_21_01
Importe: 7.221,89 €
Duración: 31/12/2021 to 31/12/2025

Deciphering the molecular signatures of gestational food cravings as drivers of eating disorders in the offspring

IP: HADDAD TOVOLLI, ROBERTA
Financiador: Brain and Behaviour Research Foundation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: BBRF_YI_23
Importe: 64.218 €
Duración: 15/01/2024 to 14/01/2026

A new target for the treatment of acute and chronic itch

IP: Gasull Casanova, Xavier
Financiador: LEO FOUNDATION
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LF-OC-22-001114
Importe: 351.488,65 €
Duración: 01/02/2023 to 31/01/2026

Type 2 inflammation and olfactory loss in chronic rhinosinusitis with nasal polyps: Role of Mepolizumab in olfactory cell neurogenesis

IP: MULLOL MIRET, JOAQUIM
Financiador: Glaxosmithkline Research & Development Limited
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 14859
Importe: 389.318,8 €
Duración: 01/09/2023 to 14/03/2026

Preclinical evaluation of Lilly LRRK2 inhibitors for Parkinson's disease using phosphoproteomic analysis

IP: EZQUERRA TRABALON, MARIO ANTONIO
Financiador: LILLY, SAU
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LILLY_RAP_23_01
Importe: 242.258,79 €
Duración: 19/03/2024 to 18/03/2026

Dissecting the role of the 14q32 region in hepatoblastoma "Hblast14"

IP: SANCHO BRU, PAU
Financiador: Worldwide Cancer Research
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 23-0356
Importe: 245.573,14 €
Duración: 01/04/2023 to 31/03/2026

Dissecting the cellular and molecular atlas of Rheumatoid Arthritis (RA) in sustained remission to identify pathways maintaining Remission and Triggering Flares

IP: CAÑETE CRESPILLO, JUAN DE DIOS
Financiador: FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: FOREUM_21_02
Importe: 90.000 €
Duración: 01/04/2023 to 31/03/2026

Decoding tanycytic mitochondrial dynamics in nutrient sensing and metabolic health.

IP: CLARET CARLES, MARC
Financiador: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EFSD/LILLY_23_01
Importe: 100.000 €
Duración: 01/07/2024 to 30/06/2026

ATLAX - Characterizing the signals from adipo-liver axis in NASH and unveiling their utility as disease biomarkers.

IP: GRAUPERA GARCIA MILA, ISABEL
Financiador: PFIZER INC.
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: PFIZER_NASH_A_22_1
Importe: 127.775,17 €
Duración: 08/11/2023 to 30/06/2026

Mutimodal single cell profiling of tumor cell and microenvironment interactions driving clinical evolution and therapeutic responses in Mantle Cell Lymphoma

IP: CAMPO GUERRI, ELIAS
Financiador: ASTRAZENECA UK LTD.
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ASTRAZ_HEMAT_22_1
Importe: 647.255,72 €
Duración: 04/08/2022 to 03/08/2026

EHIN - Epithelioid Hemangioendothelioma International Network.

IP: RIMOLA GIBERT, JORDI
Financiador: EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EASL_RG_21_01
Importe: 50.000 €
Duración: 01/09/2021 to 31/08/2026

Transcriptomic impact of blocking IL-5 with mepolizumab on CD4+T lymphocytes from patients with EGPA. Search for predictors of response

IP: ESPIGOL FRIGOLE, GEORGINA
Financiador: Glaxosmithkline Research & Development Limited
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 219739
Importe: 164.895,2 €
Duración: 08/09/2023 to 26/02/2027

MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)

IP: BEA BOBET, SILVIA MARGARITA
Financiador: Ludwig-Maximilians-Universitaet Muenchen
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LLS_MCL_22_2
Importe: 221.720 €
Duración: 01/07/2023 to 30/06/2027

BioRTC Computational Neuroscience Course

IP: COMPTE BRAQUETS, ALBERT
Financiador: Simons Foundation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 00009921
Importe: 71.009,28 €
Duración: 01/09/2024 to 31/08/2027

Unravelling the functional role and therapeutic potential of transcription factors in chronic lymphocytic leukemia

IP: MAIQUES DIAZ, ALBA
Financiador: EHA (EUROPEAN HEMATOLOGY ASSOC.)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: RG-202310-04245
Importe: 239.281 €
Duración: 01/09/2024 to 31/08/2027

CARTALLEU - Phase 2 clinical trial to evaluate the efficacy and safety of varnimcabtagene autoleucel for relapsed/refractory adult acute lymphoblastic leukaemia

IP: DELGADO GONZÁLEZ, JULIO
Financiador: FUNDACIÓN CIENTIFICA ASOCIACIÓN ESPAÑOLA CONTRA EL CANCER
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ATTRACT_23_01
Duración: 01/04/2024 to 31/03/2029

Structural heart disease training Fellowship

IP: FREIXA ROFASTES, XAVIER
Financiador: EDWARDS LIFESCIENCES
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EDWARDSFELLOW_24_01
Importe: 18.000 €
Duración: 23/07/2024 to 31/12/9998

DIGITALLY-ENHANCED PERSONALIZED MEDICINE: ACCURATE SELECTION OF SUBJECTIVE COGNITIVE DECLINE AND MEASURING PROGRESSION OF MILD COGNITIVE IMPAIRMENT

IP: BALASA, MIRCEA
Financiador: ALTOIDA, INC.
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ADDF_2019_01
Importe: 113.500 €
Duración: 01/08/2021 to 28/02/2024

ToIDC - Impact of autologous tolerogenic dendritic cells (ToIDC) on full mismatch kidney transplantation rat model

IP: VENTURA ABREU AGUIAR, PEDRO
Financiador: PORTUGUESE TRANSPLANTATION SOCIETY
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: SPT_BAMPS_19_01
Importe: 10.000 €
Duración: 01/10/2021 to 31/03/2024

CRCNS US-Spanish Research Proposal: Circuit mechanisms of priors and learning during decision making

IP: POL SOROLLA, ALBERTO
Financiador: Massachussets Institute of Technology
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: NSF_CRCNS_21_01
Importe: 0,01 €
Duración: 01/12/2022 to 30/11/2025

Modelling Age-related Macular Degeneration with a Blood-Retinal-Barrier Biomimetic System Combining Human Pluripotent Stem Cells and Decellularized Retinal Tissue

IP: MOLINS MONTEY, BLANCA
Financiador: NOVARTIS FARMACÉUTICA, S.A
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: NOVARTIS_IIT_21_01
Importe: 37.000 €
Duración: 08/06/2022 to 31/08/2025

INTREPIBD - Identifying digital biomarkers of illNess activity and Treatment REsPonse In Bipolar Disorder .

IP: HIDALGO MAZZEI, DIEGO ALBERTO
Financiador: Milken Institute. .
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MILKEN_BD_21_01
Importe: 151.401,9 €
Duración: 10/12/2021 to 31/08/2024

Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma

IP: CAMPO GUERRI, ELIAS
Financiador: Mayo Clinic Arizona
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: NIH_PAR-16-457_01
Importe: 837.653,95 €
Duración: 19/09/2018 to 30/06/2024

European Registry of patients treated with TIPS following a standardized, state of the art, pre, peri and post procedural approach: The EUROTIPS project

IP: RIMOLA GIBERT, JORDI PRAT APARICIO, ALEIX
Financiador: EASL, European Association for Study of the Liver
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EASL_RG_19_01
Importe: 40.000 €
Duración: 20/07/2020 to 19/07/2024

Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes

IP: BEA BOBET, SILVIA MARGARITA
Financiador: Ludwig-Maximilians-Universitaet Muenchen
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LMUM_EMCLP_21_01
Importe: 5.000 €
Duración: 29/04/2022 to 28/04/2024

Tracking the origin of chronic lymphocytic leukemia progression and transformation through its genomic and transcriptonic footprints

IP: CAMPO GUERRI, ELIAS
Financiador: EHA (EUROPEAN HEMATOLOGY ASSOC.)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: RG-202012-00245
Importe: 150.000 €
Duración: 01/01/2022 to 31/12/2024

Molecular characterization of obesity/diabetes/NASH-related hepatocellular carcinoma

IP: LLOVET BAYER, JOSEP MARIA
Financiador: EASL, European Association for Study of the Liver
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EASL_JR_12_20
Importe: 120.000 €
Duración: 01/05/2021 to 30/04/2024

The Edmond J. Safra Fellowship in Movement Disorders - Hospital Clinic Barcelona

IP: CAMPO GUERRI, ELIAS & VALLDEORIOLA SERRA, FRANCESC
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-023487
Importe: 170.928 €
Duración: 01/09/2023 to 31/08/2026

BLOOD a-SYNUCLEIN AGGREGATION ASSAY AS A NOVEL DIAGNOSTIC TOOL FOR PARKINSON’S DISEASE

IP: FERNANDEZ SANTIAGO, RUBEN & COMPTA HIRNYJ, YAROSLAU
Financiador: US Department of Defence
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: DOD_PRP_23_01
Importe: 328.679,43 €
Duración: 01/09/2024 to 31/08/2026

Interaction between MRI metrics and biomarkers of chronic activity to predict disability outcomes and treatment response in multiple sclerosis

IP: LLUFRIU DURAN, SARA
Financiador: Congrex Switzerland Ltd,
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ECTRIMS_FELLOW21_02
Importe: 110.000 €
Duración: 01/11/2022 to 31/10/2024